Stem cells and regenerative medicine are emerging and promising fields both in academic and industry points of views. They are currently under active investigation worldwide and their market size is expected to grow rapidly in the near future. The Korean government is also investing a huge amount of money on these fields to promote R&D and product commercialization. However, its technical maturity is still in its infant state and many hurdles should be resolved to accelerate technology to business. I can definitely say that we have to focus in the future on innovations in technology, regulations and reimbursement. In particular, the importance of translational research and clinical studies are of no doubt in the stem cells and regenerative medicine. I am going to deal with some of these issues in more detail in the main text.